Osterweis Capital Management Inc. Buys New Position in AtriCure, Inc. $ATRC

Osterweis Capital Management Inc. bought a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 501,355 shares of the medical device company’s stock, valued at approximately $14,028,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after acquiring an additional 62,861 shares during the period. BlackRock Inc. bought a new stake in shares of AtriCure during the 2nd quarter valued at $125,198,000. Wellington Management Group LLP grew its position in shares of AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after acquiring an additional 322,818 shares during the period. First Light Asset Management LLC increased its stake in shares of AtriCure by 32.0% in the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after purchasing an additional 285,083 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of AtriCure by 8.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after purchasing an additional 75,862 shares in the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Trading Up 0.6%

ATRC stock opened at $49.28 on Tuesday. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $49.88. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of 234.68 and a beta of 1.20. The business has a 50 day simple moving average of $36.25 and a two-hundred day simple moving average of $31.89.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ATRC shares. BTIG Research raised their target price on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, UBS Group lowered their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, AtriCure has an average rating of “Moderate Buy” and a consensus price target of $48.62.

Insider Activity

In related news, insider Justin J. Noznesky sold 6,182 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the completion of the transaction, the insider directly owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Karen Prange sold 3,564 shares of AtriCure stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the sale, the director owned 22,809 shares in the company, valued at approximately $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 44,246 shares of company stock valued at $1,691,895 in the last quarter. Company insiders own 4.00% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.